PuREC Co., Ltd.

Basic information

Location (HQ)

Shimane, JP

Other location(s)

Tokyo, JP

Spinout from

Shimane University Medical School

Website

CEO

Established in 

2016

Business descriptions

PuREC is currently preparing the IND for hypophosphatasia (a rare bone-formation deficiency disease for new born babies) with our uniquely purified MSC (mesenchymal stem cell). Two other orthopedic disease are expected to file IND in a few years. We are confident that our specially purified MSC, called “REC”, can be applied also for other disease areas as well.
As our first-in-human trial is expected to start in 2021, we seek for license partners and investors to solidify furhter development; esipecially in Europe and U.S.

Business field

Shimane University Medical School

Keywords

MSC

stem cell therapy

hypophosphatasia

disc herination

TRL

6

Key literatures

Company values

Number of filed patents

4

Patent IDs

Total patent value (USD)

No data

Business stage

Series A stage

Types of requested collaborations

R&D Collaboration, Investment, license partner

Ideal exit model

IPO in Japan

Introduction

PuREC is a Shimane University spinout company having patented technologies to produce extremely purified MSC, or mesenchymal stem cells. PuREC's REC is coming from Rapidly Expanding Cells enabling to obtain 10^12 ordered pure cells within 12 weeks without requiring complicated methodologies including gene-modification. 



This base-technology can be used for many types of applications including cell therapy field for orphan diseases. PuREC has been running collaborative research and joint projects with Hokkaido and Shimane Universities and Japanese corporates. PuREC is prepared for the first in-human trial for hypophosphatasia (a rare bone-formation deficiency disease for new-born babies), ready for its clinical trial in 2021. Also two other orthopaedic applications (e.g. disc herniation and joint diseases) will be in IND phase within a few years. Those three disease targets are in ongoing pipeline with challenging total $23.5bn world-wide market.



Using the same platform technology, PuREC is looking for business partners to invest on the following disease types:



Crohn's disease

GvHD (Graft-versus-host disease)

Spinal cord injury

Stroke

Brain injury

Other joint diseases

Licensing opportunity

(focusing on EU and US market)



Hypophosphatasia

Disc herniation

Joint disease

New applications including immunology diseases

Investment opportunity

Target $10M by 2022



Target other disease target POC

Create global business development team



Global investors outside Japan are also welcome